Article
Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.
Molecular cancer therapeutics - 1 Apr 2013
Gunawardane Ruwanthi N, Nepomuceno Ronald R, Rooks Allison M, Hunt Jeremy P, Ricono Jill M, Belli Barbara, Armstrong Robert C
Abstract excerpt
Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML). FLT3-activating internal tandem duplication (ITD) mutations are found in approximately 30% of patients with AML and are associated with poor outcome in this patient population. Quizartinib (AC220) has previously been shown to be a potent and selective FLT3 inhibitor. In the current study, we expand on previous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.